Will cannabinoids replace my duloxetine and pregabalin?

Not automatically. The doctor will usually keep your current regimen during the cannabinoid trial and only consider tapering once a response is established. Stopping conventional medications first risks losing the partial benefit you already have.

How quickly will I know if it works for fibromyalgia?

Fibromyalgia responses are typically slower than acute pain. The doctor will usually re-evaluate at 6–8 weeks of stable dosing. If pain, sleep, and daily function have not improved measurably by then, the regimen is changed or stopped rather than persisted with.

Will it help with the "fibro fog"?

Mixed. CBD-leaning regimens are sometimes well tolerated cognitively. THC-dominant regimens can worsen brain fog at higher doses, particularly daytime. Clear cognitive endpoints — for instance, work-task tracking or a brief monthly cognitive self-assessment — are part of how the doctor will measure benefit versus harm.

Should I exercise while on cannabinoid therapy for fibromyalgia?

Yes — graded exercise is recommended in fibromyalgia (unlike ME/CFS, where it is contraindicated). The cannabinoid trial works best as part of a package that includes paced movement. Patients who use the cannabinoid as an excuse to stop activity tend to lose function faster; patients who maintain or grow activity tend to do best.

Will my medical aid cover any of this?

Most SA medical schemes do not cover Section 21 cannabinoid medication itself. The doctor consultation may be partly claimable depending on your scheme — confirm directly with your scheme. Section 21 SAHPRA fees and the medication cost are typically out-of-pocket. We disclose all fees up-front before you commit.

Condition · ICD-11 MG30.01

Fibromyalgia

Creator: Dr. Placeholder B
Published: 2026-04-16

Reviewed by Dr. Placeholder B (HPCSA MP0XXXXX · Pain Medicine) · Last updated 16 Apr 2026 · Published 16 Apr 2026

Fibromyalgia is a chronic pain syndrome characterised by widespread musculoskeletal pain, fatigue, sleep disturbance, and cognitive fog ("fibro fog"). It is one of the most commonly enquired-about indications for medical cannabis in South Africa, in part because conventional first-line therapy — duloxetine, pregabalin, low-dose tricyclics, and graded exercise programmes — often delivers only partial benefit and frequently causes intolerable side effects. Cannabinoid-based therapy is not first-line. It is sometimes considered as an adjunct after a structured trial of conventional options has been completed and documented.

What the evidence says

Walitt et al (2016 Cochrane) reviewed cannabinoids for fibromyalgia and found low-quality evidence for nabilone reducing pain and sleep disturbance, with cautious framing because of small trial sizes. Sagy et al (2019) reported a large prospective Israeli cohort showing meaningful pain and sleep improvements at 6 months under medical-cannabis prescriptions. The EULAR 2016 guideline does not endorse cannabinoids as standard fibromyalgia therapy but acknowledges patient interest. The honest summary: the evidence is moderate at best, but for patients failing conventional options, a carefully titrated trial under doctor supervision is reasonable.

How the doctor will evaluate you

You will be asked for the diagnostic basis (typically a rheumatology or pain-medicine letter), the conventional medications already trialled with response and reasons for discontinuation, current sleep and exercise patterns, and any psychiatric co-morbidity (depression and anxiety frequently co-exist and influence both treatment choice and dosing). A balanced THC:CBD or CBD-leaning formulation is usually the starting point, with conservative titration to manage daytime function. Doctors generally avoid initiating cannabinoid therapy in fibromyalgia patients who have not first attempted graded exercise — without that foundation, the cannabinoid effect tends to plateau quickly.

When to see a doctor urgently

Severe untreated depression or active suicidal ideation — psychiatric stabilisation comes first
History of psychosis or strong family history — THC components may be unsuitable
Pregnancy or breastfeeding — cannabinoid therapy is deferred
New focal neurological symptoms — exclude alternative diagnosis (MS, neuropathy) before attributing to fibromyalgia

If any of the above apply, seek in-person medical care — do not wait for a remote Section 21 consultation.

The South African Section 21 pathway

Fibromyalgia is regularly evaluated under the SA Section 21 pathway as a refractory chronic-pain indication. Applications are stronger when supported by a documented diagnostic workup, a structured trial of duloxetine and pregabalin, and a current functional baseline (e.g. PROMIS or fibromyalgia impact questionnaire). Authorisations are typically time-limited and re-assessed at the 6-month renewal against measurable function — not just symptom relief.

Frequently asked

Will cannabinoids replace my duloxetine and pregabalin?: Not automatically. The doctor will usually keep your current regimen during the cannabinoid trial and only consider tapering once a response is established. Stopping conventional medications first risks losing the partial benefit you already have.
How quickly will I know if it works for fibromyalgia?: Fibromyalgia responses are typically slower than acute pain. The doctor will usually re-evaluate at 6–8 weeks of stable dosing. If pain, sleep, and daily function have not improved measurably by then, the regimen is changed or stopped rather than persisted with.
Will it help with the "fibro fog"?: Mixed. CBD-leaning regimens are sometimes well tolerated cognitively. THC-dominant regimens can worsen brain fog at higher doses, particularly daytime. Clear cognitive endpoints — for instance, work-task tracking or a brief monthly cognitive self-assessment — are part of how the doctor will measure benefit versus harm.
Should I exercise while on cannabinoid therapy for fibromyalgia?: Yes — graded exercise is recommended in fibromyalgia (unlike ME/CFS, where it is contraindicated). The cannabinoid trial works best as part of a package that includes paced movement. Patients who use the cannabinoid as an excuse to stop activity tend to lose function faster; patients who maintain or grow activity tend to do best.
Will my medical aid cover any of this?: Most SA medical schemes do not cover Section 21 cannabinoid medication itself. The doctor consultation may be partly claimable depending on your scheme — confirm directly with your scheme. Section 21 SAHPRA fees and the medication cost are typically out-of-pocket. We disclose all fees up-front before you commit.

Related conditions

Glossary — terms used on this page

Quick definitions for terminology referenced above. Each links to a fuller entry.

Think this might apply to you? An HPCSA-registered doctor will review your case.

START ELIGIBILITY REVIEW

R500 consultation · R400 SAHPRA fee per product · 3–7 days end-to-end